Observational study on neuroendocrine tumors in the gastroenteropancreatic tract and lungs
Observational Study on Clinical, Laboratory, Anatomopathological and Molecular Characteristics and Their Prognostic and Predictive Value in Patients With Neuroendocrine Tumors of the Gastroenteropancreatic Tract and Pulmonary Treated at Fondazione Policlinico Agostino Gemelli (FPG)-IRCCS
This study looks at the different features of neuroendocrine tumors in the digestive system and lungs to help doctors make better treatment decisions for patients with these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 650 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Rome) |
| Trial ID | NCT06402695 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the clinical, laboratory, pathological, and molecular characteristics of patients diagnosed with gastroenteropancreatic and pulmonary neuroendocrine tumors (NETs). It focuses on understanding the heterogeneity of these tumors and identifying new prognostic and predictive biomarkers that can enhance classification and staging. The study will include patients who have a histological diagnosis and radiological evidence of disease, and it will collect data to better inform therapeutic decisions. By examining these characteristics, the study seeks to address the clinical need for improved prognostic tools in NET management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a histological diagnosis of gastroenteropancreatic or pulmonary neuroendocrine tumors.
Not a fit: Patients without a histological diagnosis or those lacking sufficient clinical data for survival analysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prognostic tools and treatment strategies for patients with neuroendocrine tumors.
How similar studies have performed: While there is ongoing research in the field of neuroendocrine tumors, this specific approach to identifying new biomarkers is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histological diagnosis of gastroenteropancreatic or pulmonary NET * age ≥ 18 years; * radiological evidence of resectable/locally advanced/metastatic disease; * signing of informed consent; * at least one visit following the first oncological visit. Exclusion Criteria: * absence of clinical data that allow adequate definition of survival (primary endpoint of the study); * absence of histological diagnosis; * failure to sign the informed consent.
Where this trial is running
Rome
- Fondazione Policlinico Universitario Agostino Gemelli - IRCCS — Rome, Italy (Recruiting)
Study contacts
- Principal investigator: Giovanni Schinzari — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study coordinator: Maria Grazia Maratta, MD
- Email: mariagrazia.maratta@guest.policlinicogemelli.it
- Phone: +39 0630156318
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.